iTeos Therapeutics SA is a spin-off of the Ludwig Cancer Research (UCL-LICR) and the UCL de Duve Institute. The company was founded in 2011 by Pr B. van den Eynde and Dr M. Detheux, after ten years of research. iTeos is a private, biology-driven and preclinical-stage company, which leverages UCL and LICR’s unique expertise in tumor immunology to focus on identification and development of small molecule drugs.

iTeos’ objective is to develop small molecules designed to modify the metabolism of tumor microenvironment by inhibiting the cancer-induced immune suppression. Targeting this resistance mechanism can enhance the clinical effectiveness of both standard care treatments and newer immuno-modulatory treatments. iTeos plans to complete the clinical development stage of its first two programs by 2016.

Next step: clinical trial phase I in early 2016
Second financial round 2015
Spin-off creation August 2011
First Spin-Off grant 2010
Research topic initiated 2000

Transform cancer into a curable disease

iTeos Therapeutics: a key player for the world of tomorrow